Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
INCA33890 · 2 trials · 4 indications
Defined as the time from the date of randomization to the date of the first documented progression as determined by the investigator per Response Evaluation Criteria in Solid Tumours (RECIST) v1.1 or death due to any cause.
| Arm | Type | Description |
|---|---|---|
| INCA33890 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose. |
| Placebo | PLACEBO_COMPARATOR | Placebo will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose. |
| Part 1a - Dose Escalation Monotherapy | EXPERIMENTAL | INCA33890 will be administered at the protocol-defined dose based on cohort assignment. |
| Part 1b-Dose Expansion Monotherapy | EXPERIMENTAL | INCA33890 will be administered at the protocol-defined dose based on cohort assignment. |
| Part 2a - Dose Escalation Combination Therapy - Group 1 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment. |
| Part 2a - Dose Escalation Combination Therapy - Group 2 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. |
| Part 2a - Dose Escalation Combination Therapy - Group 3 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. |
| Part 2a - Dose Escalation Combination Therapy - Group 4 | EXPERIMENTAL | INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment. |
| Part 2a - Dose Escalation Combination Therapy - Group 5 | EXPERIMENTAL | INCA33890 will be administered in combination with ADG126 at the protocol-defined dose based on cohort assignment. |
| Part 2b - Dose Expansion Combination Therapy - Group 1 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab at the protocol-defined dose based on cohort assignment. |
| Part 2b - Dose Expansion Combination Therapy - Group 2 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFIRI at the protocol-defined dose based on cohort assignment. |
| Part 2b - Dose Expansion Combination Therapy - Group 3 | EXPERIMENTAL | INCA33890 will be administered in combination with bevacizumab and FOLFOX at the protocol-defined dose based on cohort assignment. |
| Part 2b - Dose Expansion Combination Therapy - Group 4 | EXPERIMENTAL | INCA33890 will be administered in combination with cetuximab at the protocol-defined dose based on cohort assignment. |
| Part 2b - Dose Expansion Combination Therapy - Group 5 | EXPERIMENTAL | INCA33890 will be administered in combination with ADG126 at the protocol-defined dose based on cohort assignment. |
| Name | Type | Description |
|---|---|---|
| INCA33890 | DRUG | INCA33890 will be administered at protocol defined dose. |
| Placebo | DRUG | Placebo will be administered at protocol defined dose. |
| Bevacizumab | DRUG | Bevacizumab will be administered at protocol defined dose. |
| FOLFOX | DRUG | FOLFOX will be administered at protocol defined dose. |
| FOLFIRI | DRUG | FOLFIRI will be administered at protocol defined dose. |
| Cetuximab | DRUG | Cetuximab will be administered at protocol defined dose. |
| ADG126 | DRUG | ADG126 will be administered at protocol defined dose. |
Inclusion Criteria: * Stage IV colorectal adenocarcinoma not amenable to curative resection. * No prior systemic treatment for unresectable or metastatic disease. Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment...
Top 20 of 76 competitors
INCA33890 is an investigational small molecule being studied for the first-line treatment of metastatic microsatellite stable colorectal cancer, in combination with standard-of-care chemotherapy and bevacizumab. It is also being evaluated in a Phase 1 study for advanced or metastatic solid tumors. The drug is not yet approved and remains in clinical development.
INCA33890 targets TGFβR2xPD-1, a bispecific mechanism that engages both transforming growth factor beta receptor 2 and programmed cell death protein 1. This dual targeting is designed to modulate immune and tumor signaling pathways relevant to oncology. The drug is a small molecule being developed by Incyte Corporation.
INCA33890 is developed by Incyte Corporation, a biopharmaceutical company traded on the Nasdaq under the ticker INCY. Incyte is conducting clinical trials of INCA33890 in oncology indications, including colorectal cancer and other solid tumors.
INCA33890 is in Phase 3 clinical development for metastatic microsatellite stable colorectal cancer, based on a recruiting Phase 3 trial. It is also being studied in an earlier Phase 1 trial for advanced or metastatic solid tumors. The drug is investigational and not yet approved by regulatory authorities.
INCA33890 is being evaluated in two recruiting trials. NCT07284849 is a Phase 3 study testing the drug with chemotherapy and bevacizumab in first-line metastatic microsatellite stable colorectal cancer, enrolling 700 participants. NCT05836324 is a Phase 1 safety study in advanced or metastatic solid tumors, enrolling 570 participants across multiple countries.
No alternative names for INCA33890 have been disclosed. The drug is identified solely by its code name INCA33890 in clinical trial registries and by its developer, Incyte Corporation. It is a distinct investigational small molecule targeting TGFβR2xPD-1.